Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome
- PMID: 10077052
- PMCID: PMC1191705
- DOI: 10.1097/00000658-199903000-00013
Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome
Abstract
Objective: This single-institution experience retrospectively reviews the outcomes of patients undergoing reexploration for periampullary carcinoma at a high-volume center.
Summary background data: Many patients are referred to tertiary centers with periampullary carcinoma after their tumors were deemed unresectable at previous laparotomy. In carefully selected patients, tumor resection is often possible; however, the perioperative results and long-term outcome have not been well defined.
Methods: From November 1991 through December 1997, 78 patients who underwent previous exploratory laparotomy and/or palliative surgery for suspected periampullary carcinoma underwent reexploration. The operative outcome, resectability rate, pathology, and long-term survival rate were compared with 690 concurrent patients who had not undergone previous exploratory surgery.
Results: Fifty-two of the 78 patients (67%) undergoing reexploration underwent successful resection by pancreaticoduodenectomy; the remaining 26 patients (34%) were deemed to have unresectable disease. Compared with the 690 patients who had not undergone recent related surgery, the patients in the reoperative group were similar with respect to gender, race, and resectability rate but were significantly younger. The distribution of periampullary cancers by site in the reoperative group undergoing pancreaticoduodenectomy (n = 52) was 60%, 19%, 15%, and 6% for pancreatic, ampullary, distal bile duct, and duodenal tumors, respectively. These figures were similar to the 65%, 14%, 16% and 5% for resectable periampullary cancers found in the primary surgery group (n = 460). Intraoperative blood loss and transfusion requirements did not differ between the two groups. However, the mean operative time was 7.4 hours in the reoperative group, significantly longer than in the control group. On pathologic examination, reoperative patients had smaller tumors, and the percentage of patients with positive lymph nodes in the resection specimen was significantly less. The incidence of positive margins was similar between the two groups. Postoperative lengths of stay, complication rates, and perioperative mortality rates were not higher in reoperative patients. The long-term survival rate was similar between the two resected groups, with a median survival of 24 months in the reoperative group and 20 months in those without previous exploration.
Conclusions: These data demonstrate that patients undergoing reoperation for periampullary carcinoma have similar resectability, perioperative morbidity and mortality, and long-term survival rates as patients undergoing initial exploration. The results suggest that selected patients considered to have unresectable disease at previous surgery should undergo restaging and reexploration at specialized high-volume centers.
Similar articles
-
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8. doi: 10.1097/00000658-200209000-00012. Ann Surg. 2002. PMID: 12192322 Free PMC article. Clinical Trial.
-
Reoperative pancreaticoduodenectomy for periampullary carcinoma.ANZ J Surg. 2005 Jul;75(7):520-3. doi: 10.1111/j.1445-2197.2005.03438.x. ANZ J Surg. 2005. PMID: 15972035
-
Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s.J Am Coll Surg. 1999 Jun;188(6):658-66; discussion 666-9. doi: 10.1016/s1072-7515(99)00049-6. J Am Coll Surg. 1999. PMID: 10359359
-
Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?Am J Surg. 2001 Aug;182(2):120-9. doi: 10.1016/s0002-9610(01)00686-9. Am J Surg. 2001. PMID: 11574081 Review.
-
Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct.Ann Surg. 1989 Oct;210(4):544-54; discussion 554-6. doi: 10.1097/00000658-198910000-00015. Ann Surg. 1989. PMID: 2679459 Free PMC article. Review.
Cited by
-
Second-look operation for unresectable pancreatic ductal adenocarcinoma at a high-volume center.Ann Surg Oncol. 2008 Jan;15(1):186-92. doi: 10.1245/s10434-007-9535-0. Epub 2007 Oct 18. Ann Surg Oncol. 2008. PMID: 17943388 Free PMC article.
-
Neoadjuvant therapy for pancreatic ductal adenocarcinoma-real effects or patient selection?Hepatobiliary Surg Nutr. 2018 Aug;7(4):289-291. doi: 10.21037/hbsn.2018.03.11. Hepatobiliary Surg Nutr. 2018. PMID: 30221156 Free PMC article. No abstract available.
-
Pancreaticoduodenectomy: role of interventional radiologists in managing patients and complications.J Gastrointest Surg. 2003 Feb;7(2):209-19. doi: 10.1016/s1091-255x(02)00193-2. J Gastrointest Surg. 2003. PMID: 12600445
-
Reoperative surgery for chronic pancreatitis: is it safe?World J Surg. 2006 Jul;30(7):1321-8. doi: 10.1007/s00268-005-7908-8. World J Surg. 2006. PMID: 16794906
-
Contemporary single-center surgical experiences in redo procedures of the pancreas: improved outcome and reduction of operative risk.J Gastrointest Surg. 2011 Jan;15(1):191-8. doi: 10.1007/s11605-010-1384-7. Epub 2010 Nov 12. J Gastrointest Surg. 2011. PMID: 21072690
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical